Inhibikase Therapeutics (IKT) Share-based Compensation (2020 - 2026)
Inhibikase Therapeutics (IKT) reported Share-based Compensation of $5.6 million for Q1 2026, up 172.24% year-over-year from $2.0 million in Q1 2025, and up 22.63% quarter-over-quarter from $4.5 million in Q4 2025.
Inhibikase Therapeutics (IKT) Share-based Compensation (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has 7 years of Share-based Compensation data on file, last reported at $5.6 million in Q1 2026.
- Share-based Compensation for Q1 2026 came in at $5.6 million, up 172.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.8 million (up 85.87% YoY), and the FY2025 annual result was $15.3 million, up 88.07% from the prior year.
- Share-based Compensation rose to $5.6 million in Q1 2026 per IKT's latest filing, from $4.5 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $7.9 million in Q4 2024 and troughed at $30697.0 in Q2 2024.
- A 5-year average of $1.8 million and a median of $129781.0 in 2023 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2025: Share-based Compensation slumped 79.15% in 2022, then jumped 13610.6% in 2025.
- A 5-year view of Share-based Compensation shows it stood at $100363.0 in 2022, then advanced by 21.81% to $122249.0 in 2023, then jumped by 6369.14% to $7.9 million in 2024, then tumbled by 42.67% to $4.5 million in 2025, then advanced by 22.63% to $5.6 million in 2026.
- Business Quant data shows IKT's Share-based Compensation at $5.6 million in Q1 2026, $4.5 million in Q4 2025, and $4.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 305,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 26.47 Mn |
| 10 | Inhibikase Therapeutics | 285.17 Mn | 114.80 Mn | - | 5.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.56 Mn |
| Mar 31, 2026 | 5.56 Mn |
| Dec 31, 2025 | 4.53 Mn |
| Dec 31, 2025 | 4.53 Mn |
| Sep 30, 2025 | 4.53 Mn |
| Sep 30, 2025 | 4.53 Mn |
| Jun 30, 2025 | 4.21 Mn |
| Jun 30, 2025 | 4.21 Mn |
| Mar 31, 2025 | 2.04 Mn |
| Mar 31, 2025 | 2.04 Mn |
| Dec 31, 2024 | 7.91 Mn |
| Dec 31, 2024 | 7.91 Mn |
| Sep 30, 2024 | 148,024.00 |
| Sep 30, 2024 | 148,024.00 |
| Jun 30, 2024 | 30,697.00 |
| Jun 30, 2024 | 30,697.00 |
| Mar 31, 2024 | 53,434.00 |
| Mar 31, 2024 | 53,434.00 |
| Dec 31, 2023 | 122,249.00 |
| Dec 31, 2023 | 122,249.00 |